Woman sheds 4 stone(25 kilos) in 4 months on Mounjaro, then suffers liver failure—how the drug works and its risks
Aimee Chapman, 34, from Southampton, lost four stone in just four months using Mounjaro—but her rapid transformation came at a devastating cost. The former waitress was admitted to intensive care last summer with liver failure and a perforated oesophagus, complications doctors directly linked to the weight-loss injection.
Tired of too many ads? go ad free now
Chapman had purchased Mounjaro from a major online pharmacy in March 2024, hoping that losing weight would help her be 'taken more seriously' by doctors after being diagnosed with fibromyalgia, a chronic pain disorder.
At first, the results were everything she hoped for. But just a few months in, her health began to unravel.
"I couldn't really do much. I was only eating a couple of times a week," she said. "I stopped being able to walk.
I would take a couple of steps and have to stop. Then I couldn't stop being sick. I was throwing up all the time and started throwing up blood. I was sick between 50 and 60 times."
Chapman collapsed multiple times. "My husband came home and found me passed out on the hallway one night," she said. Initially, she believed it was a virus. 'I was in a bit of denial about it being linked to the jab because I was fine up until now.'
It wasn't until she experienced severe chest pains that she went to Winchester Hospital A&E.
There, doctors discovered a hole in her oesophagus—allowing air to leak around her heart and lungs. As her blood pressure and potassium levels dropped, she was transferred to intensive care at Southampton General Hospital, where doctors found her liver was 'failing.' A transplant was considered.
"They had said it was down to the weight-loss jab but they didn't know why or how to fix it," she said. "I was terrified. It all happened so quickly… I was told the hole in the oesophagus can kill people and I may have needed a new liver.
Tired of too many ads? go ad free now
They said I could've died."
Though her condition was stabilized within two weeks, her ordeal continued. By September, she began losing large clumps of hair—eventually diagnosed as a vitamin B12 deficiency. 'It kept happening and the handfuls kept getting bigger. I would be so sad,' she said. 'My hair was such a massive part of my identity and to cut it off just felt really traumatic.'
While she doesn't want to 'tell people what they can and can't take,' Chapman says, 'I regret ever taking them.
I'd say to other people thinking about trying them, don't do it online, go through your doctor who can give you blood tests and check how you're doing.'
What exactly is Mounjara?
According to Drugs.com, Mounjaro (tirzepatide) is a once-weekly injection primarily prescribed to manage type 2 diabetes by lowering blood sugar levels. In addition to its intended purpose, the medication is also known to promote weight loss. It is meant to be used alongside a healthy diet and regular exercise.
The U.S. Food and Drug Administration (FDA) approved Mounjaro on May 13, 2022, and got a
at the end of 2023 for weight loss in adults. Currently, there is no generic version available. Tirzepatide is sold under two brand names—Mounjaro and Zepbound—both manufactured by Eli Lilly and Company. While they contain the same active ingredient, they are approved for different medical uses.
How does Mounjaro work?
According to the National Library of Medicine, mounjaro (tirzepatide) works through a unique dual-action approach by targeting two key gut hormone receptors. Here's how it helps manage blood sugar and promote weight loss:
Activates Two Hormone Receptors
Slows Down Stomach Emptying
Controls Appetite
Increases Satiety
Influences Brain Reward Pathways
What are the known side effects?
Like many medications in its class, Mounjaro is associated with a range of side effects, most of which involve the gastrointestinal (GI) system. According to Eli Lilly and Co. and the U.S. Food and Drug Administration (
), the most commonly reported side effects include:
Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain or discomfort
Decreased appetite
Indigestion or heartburn
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Eli Lilly says its anti-obesity pill matches Ozempic
Eli Lilly's Orforglipron, an anti-obesity pill, demonstrated significant weight loss and blood sugar reduction in clinical trials, rivaling Novo Nordisk's Ozempic. The company plans to submit Phase-III trial data to regulators by year-end, anticipating approvals from 2026. The 36 mg dose resulted in an average weight loss of 7.9% over 40 weeks. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads New Delhi: Eli Lilly said on Saturday that its anti-obesity pill Orforglipron , has shown significant results during clinical trials in reducing weight and lowering blood sugar in diabetes patients, comparable to Novo Nordisk 's anti-diabetes drug Ozempic The US drug maker aims to submit the Phase-III trial data to regulators by the end of this year and expects to get regulatory approvals from 2026, it said. The results were announced at the annual meeting of the American Diabetes Association and published in the New England Journal of Lilly also makes blockbuster drug Tirzepatide for type-2 diabetes under the Mounjaro brand and chronic weight management under the brand Zepbound. Both are administered via as well as Tirzepatide are GLP-1 drugs , which mimic a natural gut hormone that controls sugar levels and 40-week trial of the new pill tested three doses of Orforglipron: 3 milligrams, 12 milligrams and 36 milligrams. All were found to be effective at lowering blood sugar, the company 12 mg and 36 mg doses also showed clinically meaningful and statistically significant reductions in body weight compared to a placebo, the company said. The 36 mg dose led to an average weight loss of 7.9% over 40 weeks.
Time of India
4 hours ago
- Time of India
Major chocolate recall sweeps U.S stores — here's why your favorite sweet treat might be unsafe
Weaver Nut Company is recalling certain semi-sweet chocolate nonpareils distributed throughout the United States. If you recently purchased semi-sweet chocolate nonpareils from a grocery or retail store, you should double-check the lot number. Major chocolate recall sweeps U.S. stores: The U.S. Food and Drug Administration (FDA) announced in a news release on Wednesday that Weaver Nut Company was recalling its semi-sweet chocolate nonpareils with white or Christmas-colored seeds, with particular lot codes, due to possible unreported milk allergies, as per a report by Newsweek. Although no illnesses have been reported, people who are allergic to milk face a serious risk. The chocolates were sold through supermarkets and retail stores throughout the United States. ALSO READ: McDonald's boycott June 24: Who's behind it, why it's happening, and how long it will last Why is your favourite sweet treat unsafe? According to the FDA's release, the problem was discovered after a wholesale customer complained about differences in product specifications. Live Events The chocolates were labelled as being free of milk, but later laboratory testing revealed that they did contain milk proteins, it added. It further stated that consuming the affected items could result in severe or fatal allergic reactions for people with a milk allergy or severe sensitivity. One of the top nine allergens that the FDA requires to be declared is milk, and improper labelling can be very risky. Why is this recall important? According to the Pennsylvania-based Weaver Nut Company, the recall is a preventative step to protect the public's health. The business is taking all necessary steps to ensure the safety of its products. Which chocolates are affected? Customers are advised to verify product lot codes and return or dispose of any impacted items. Throw away the items or return them to the store for a complete refund. Lot numbers 204206, 204207, 204208, 204209, 204212, 224225 are for Item 47518-Nonpareil, Semi-Sweet Chocolate (Christmas Seeds). Lot numbers 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, and 145210-1 are for Item D2645, Nonpareils, Semi-Sweet Chocolate (White Seeds), as per a report by Newsweek. FAQs What do I do if I have these chocolates? Check the lot number, and if it is recalled, do not eat it. Return it for a refund or dispose of it. Why is the recall so serious? Milk is a major allergen, and consuming it when allergic can result in serious or life-threatening reactions. Economic Times WhatsApp channel )
Time of India
20 hours ago
- Time of India
Dose of hope
Times of India's Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the news and issues of the day. To really help, new HIV vax has to be made cheap A pill to treat multidrug-resistant HIV, lenacapavir, has been approved by US drug regulator FDA as a preventive vaccine. This is a huge deal – incidence of HIV may have declined since 1990s but even today about 13L people globally are infected by the virus every year. But its price is an obstacle. Sold for $28,218 per year in US, it's prohibitive even for high-income nations. Pharma company Gilead that manufactures lenacapavir has reportedly tied up with over 100 middle- and low-income countries for manufacture of generics pending approvals. But access likely will still be tricky for poorer African countries that bear the HIV burden. Drugs to prevent HIV transmission have been around almost a decade, but a daily dosage regimen makes these unreliable. People forget and there's the stigma/doubt in partners that a daily dose is preventive. Lenacapavir needs to be taken just twice a year. Its long-lasting effect in preventing infection – almost 100% in adults and adolescents – is thus the best bet today. Also because HIV research in US bears the additional burden of Trump administration's slashed funds. An effective vaccine for HIV has been elusive for decades because of its rapid mutations. Several mRNA vaccines, like those developed for Covid and considered the most promising, are in clinical trials. But since Jan, under Trump's health secretary Bob Kennedy Jr, NIH stopped funding hundreds of such HIV vaccine-related research. This is what makes repurposed lenacapavir a lifeline, provided it's made affordable. Facebook Twitter Linkedin Email This piece appeared as an editorial opinion in the print edition of The Times of India.
